6-Thioguanine Inhibits EV71 via BIRC3-Mediated Autophagy Suppression: Evidence and Implications

Study Background and Research Question

Hand, foot, and mouth disease (HFMD) is a significant pediatric health threat, particularly in the Asia-Pacific region, with Enterovirus 71 (EV71) being a principal causative agent. While inactivated vaccines targeting select EV71 serotypes have reduced the disease burden, no broadly effective antiviral therapy exists, and severe cases can lead to neurological complications and fatalities. Emerging evidence suggests that host cell processes such as autophagy may be exploited by viral pathogens to facilitate their replication. Against this backdrop, the current study by You et al. (2025) set out to investigate whether 6-thioguanine (6-TG), a thiopurine drug with established anticancer and anti-inflammatory uses, can inhibit EV71 infection and to elucidate the underlying molecular mechanisms.

Key Innovation from the Reference Study

The pivotal advance of this work lies in the identification of 6-TG as a highly selective and potent inhibitor of EV71 replication in vitro. Notably, the study uncovers that 6-TG targets the host pathway of autophagy by downregulating BIRC3 (baculoviral IAP repeat containing 3), a protein implicated in autophagic flux. This mechanistic connection between a clinically approved DNA base analog and the modulation of virus-induced autophagy represents a novel therapeutic strategy for combating EV71 and potentially other related viral pathogens.

Methods and Experimental Design Insights

You et al. utilized a combination of virological, molecular, and cytotoxicity assays to delineate the effects of 6-TG on EV71 infection. The human colorectal adenocarcinoma cell line HT-29 was employed as the cellular model. Key methodological elements included:

• Quantification of EV71 RNA and VP1 protein expression by RT-qPCR and immunoblotting, respectively, to assess viral replication.
• Measurement of infectious viral progeny in supernatant by plaque assay.
• Determination of the 50% cytotoxic concentration (CC₅₀) and 50% inhibitory concentration (IC₅₀) of 6-TG to evaluate selectivity and potency.
• Analysis of autophagy markers and BIRC3 expression through immunoblotting and related assays.

Importantly, the authors compared the antiviral selectivity index (SI) of 6-TG with that of ribavirin, a broad-spectrum nucleoside analog, to contextualize therapeutic potential.

Core Findings and Why They Matter

The study reports several critical outcomes:

• Potent inhibition of EV71 replication: 6-TG treatment resulted in a marked decrease in EV71 mRNA, VP1 protein, and viral progeny production in HT-29 cells.
• High selectivity and low cytotoxicity: The IC₅₀ for EV71 inhibition was 0.93 μM, while the CC₅₀ exceeded 2000 μM, yielding a selectivity index (>2150) that is substantially higher than ribavirin (SI > 66.7), according to the reference study.
• Mechanistic insight: 6-TG downregulated BIRC3, which led to reduced autophagic activity in EV71-infected cells. Given that EV71 exploits autophagy for replication, this suppression of BIRC3-mediated autophagy directly impaired viral propagation.

These findings are significant because they not only validate 6-TG as a promising lead for antiviral drug repurposing against EV71, but also highlight the therapeutic potential of targeting virus-induced autophagy as an antiviral strategy.

Comparison with Existing Internal Articles

While the reference paper focuses on antiviral mechanisms involving autophagy and BIRC3, several internal articles address the role of epigenetic modulation—particularly DNA methyltransferase inhibition—in disease models:

• The review on RG108 discusses a potent DNA methyltransferase inhibitor that reverses aberrant methylation and reactivates silenced tumor suppressor genes, providing a robust tool for epigenetic gene regulation modulation in cancer research.
• Another study highlights chemical induction of spermatogonia-like cells, underscoring the broader application of DNA methyltransferase inhibition in developmental biology and cell differentiation.
• RG108's pharmacokinetic profile, as detailed in a dedicated article, demonstrates its suitability for in vivo epigenetic studies without the cytotoxicity seen in nucleosidic analogs.

Although the direct mechanisms differ—autophagy regulation versus DNA methylation—both lines of research illustrate the value of small-molecule modulators in dissecting disease-relevant cellular pathways and developing targeted interventions. Researchers interested in viral pathogenesis or epigenetic modulation can draw methodological parallels from these studies, particularly in terms of small molecule screening, selectivity index determination, and mechanistic validation.

Limitations and Transferability

The findings from You et al. are compelling, but several limitations should be noted. The study was conducted exclusively in vitro using a single human cell line; the broader relevance to primary cells or in vivo systems remains to be established. The antiviral mechanism centers on BIRC3-mediated autophagy, but off-target effects of 6-TG and potential impacts on host cell homeostasis require further study to assess therapeutic windows and safety. Additionally, while 6-TG is FDA-approved for other indications, its repurposing for antiviral therapy would necessitate comprehensive pharmacodynamic and pharmacokinetic evaluations in the context of EV71 infection.

Why this cross-domain matters, maturity, and limitations

This study exemplifies a successful cross-domain approach by repurposing a well-known anticancer agent to address a major unmet need in infectious disease therapeutics. The mechanistic insight—targeting autophagy via BIRC3 downregulation—broadens our understanding of host-pathogen interactions and provides a rational basis for future antiviral drug development. However, the maturity of this approach is currently limited to preclinical cellular models; translational studies and animal models will be critical next steps.

Protocol Parameters

• 6-TG dosing in vitro: 0.5–2 μM for 24–48 hours in HT-29 cells was effective for EV71 inhibition; CC₅₀ > 2000 μM indicates a wide safety margin in this model (You et al., 2025).
• Viral challenge: Infection with EV71 at a multiplicity of infection (MOI) suitable for robust replication and measurable cytopathic effect.
• Autophagy monitoring: Immunoblotting for BIRC3 and autophagic markers (e.g., LC3, p62) recommended to confirm pathway modulation.
• Comparative selectivity assays: Include ribavirin or other reference antivirals for benchmarking selectivity index.

Research Support Resources

For researchers studying epigenetic gene regulation modulation, small molecule inhibitors such as RG108 (SKU A1913) from APExBIO provide a robust alternative for selectively inhibiting DNA methyltransferases in cell-based experiments. RG108 has been widely used to induce DNA demethylation and reactivation of silenced genes in cancer research and other epigenetic studies, with well-characterized protocols and stability profiles. This enables parallel approaches to dissecting gene regulatory networks, complementing autophagy-focused antiviral studies such as that of You et al. Researchers can refer to the product dossier for workflow recommendations and storage details.